Identification of Aryl Polyamines Derivatives as Anti-Trypanosoma cruzi Agents Targeting Iron Superoxide Dismutase

Chagas disease (CD) is a tropical and potentially fatal infection caused by Trypanosoma cruzi. Although CD was limited to Latin America as a silent disease, CD has become widespread as a result of globalization. Currently, 6-8 million people are infected worldwide, and no effective treatment is avai...

ver descrição completa

Detalhes bibliográficos
Autores: Martín-Escolano, Rubén, Molina-Carreño, Daniel, Martín-Escolano, Javier, Clares, M. Paz, Galiana-Roselló, Cristina, González-García, Jorge, Cirauqui, Nuria, Llinares, José M, Rosales, María José, García-España, Enrique, Marín, Clotilde
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Recursos:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/340091
Acesso em linha:http://hdl.handle.net/10261/340091
https://api.elsevier.com/content/abstract/scopus_id/85146751304
Access Level:acceso abierto
Palavra-chave:Trypanosoma cruzi
Aryl polyamines
Chagas disease
Chemotherapy
Drug discovery
Descrição
Resumo:Chagas disease (CD) is a tropical and potentially fatal infection caused by Trypanosoma cruzi. Although CD was limited to Latin America as a silent disease, CD has become widespread as a result of globalization. Currently, 6-8 million people are infected worldwide, and no effective treatment is available. Here, we identify new effective agents against T. cruzi. In short, 16 aryl polyamines were screened in vitro against different T. cruzi strains, and lead compounds were evaluated in vivo after oral administration in both the acute and chronic infections. The mode of action was also evaluated at the energetic level, and its high activity profile could be ascribed to a mitochondria-dependent bioenergetic collapse and redox stress by inhibition of the Fe-SOD enzyme. We present compound 15 as a potential compound that provides a step forward for the development of new agents to combat CD.